BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)
China · Delayed Price · Currency is CNY 36.67
-2.18 (-5.61%)
At close: Aug 21, 2026
SHA:688166 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 15,960 | 20,740 | 12,748 | 14,786 | 9,535 | 15,051 | |
Market Cap Growth | -65.53% | 62.70% | -13.79% | 55.07% | -36.65% | -19.85% |
Enterprise Value | 18,025 | 22,558 | 14,391 | 15,983 | 10,606 | 15,560 |
Last Close Price | 36.67 | 49.04 | 30.14 | 34.84 | 22.35 | 36.15 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 313.87 | 380.44 | 67.39 | 73.03 | 39.79 | 61.70 |
Forward PE | - | 82.45 | 52.98 | 28.00 | 28.00 | 43.06 |
PS Ratio | 12.28 | 16.95 | 9.94 | 12.54 | 9.37 | 14.30 |
PB Ratio | 5.50 | 7.29 | 5.25 | 6.12 | 4.25 | 8.64 |
P/TBV Ratio | 6.51 | 8.49 | 5.57 | 6.52 | 4.54 | 9.47 |
P/OCF Ratio | 149.25 | 63.78 | 51.91 | 75.92 | 30.63 | 85.48 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 13.87 | 18.43 | 11.22 | 13.55 | 10.43 | 14.79 |
EV/EBITDA Ratio | 76.70 | 115.60 | 48.28 | 58.11 | 39.13 | 54.92 |
EV/EBIT Ratio | 274.89 | 437.49 | 71.68 | 76.75 | 45.84 | 62.45 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.07 | 0.84 | 0.92 | 0.91 | 0.90 | 0.52 |
Debt / EBITDA Ratio | 13.14 | 11.43 | 7.16 | 7.71 | 7.17 | 3.10 |
Net Debt / Equity Ratio | 0.58 | 0.50 | 0.61 | 0.48 | 0.35 | 0.32 |
Net Debt / EBITDA Ratio | 7.67 | 7.35 | 4.93 | 4.21 | 2.92 | 1.99 |
Net Debt / FCF Ratio | -9.83 | -11.18 | -126.33 | -5.54 | -1.90 | -0.77 |
Asset Turnover | 0.22 | 0.22 | 0.25 | 0.24 | 0.27 | 0.44 |
Inventory Turnover | 1.70 | 1.69 | 1.58 | 1.74 | 1.63 | 2.33 |
Quick Ratio | 1.80 | 1.02 | 1.06 | 1.49 | 1.92 | 1.23 |
Current Ratio | 2.33 | 1.40 | 1.56 | 2.00 | 2.39 | 1.70 |
Return on Equity (ROE) | 1.85% | 1.40% | 5.83% | 7.44% | 10.62% | 14.97% |
Return on Assets (ROA) | 0.69% | 0.59% | 2.46% | 2.69% | 3.79% | 6.49% |
Return on Invested Capital (ROIC) | 1.48% | 1.26% | 4.83% | 5.79% | 7.57% | 13.37% |
Return on Capital Employed (ROCE) | 1.20% | 1.10% | 4.90% | 5.10% | 6.00% | 10.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.32% | 0.26% | 1.48% | 1.37% | 2.51% | 1.62% |
FCF Yield | -1.08% | -0.62% | -0.09% | -1.41% | -4.36% | -4.87% |
Dividend Yield | 0.04% | 0.03% | 0.32% | 0.28% | 0.51% | 0.33% |
Payout Ratio | 222.81% | 215.73% | 71.75% | 56.80% | 41.77% | 22.26% |
Buyback Yield / Dilution | -1.41% | 0.24% | 0.34% | -2.10% | -1.61% | 1.87% |
Total Shareholder Return | -1.37% | 0.28% | 0.66% | -1.82% | -1.10% | 2.21% |